No Data
Guosen: Continuously recommending Innovative Drugs and paying attention to investment opportunities in Medical Devices.
Currently, the Industry is undergoing significant supply-side structural reforms, and the collective procurement of Pharmaceuticals and Medical Devices is also nearing completion, with the expectation of entering a new growth cycle in 2025.
The Total Return for Shenzhen Mindray Bio-Medical Electronics (SZSE:300760) Investors Has Risen Faster Than Earnings Growth Over the Last Five Years
HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.
HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.
Guosen's 2025 strategy for csi sws health care index: Innovation leads to industrial upgrade.
Current domestic medical demand continues to upgrade, the macro economy is expected to gradually warm up, and under geopolitical disturbances, the country is likely to increase support for self-controllable initiatives.
These 4 Measures Indicate That Shenzhen Mindray Bio-Medical Electronics (SZSE:300760) Is Using Debt Safely
China Post Securities: The old-for-new policy has entered the implementation phase, and the medical devices sector is expected to enter a period of high performance growth.
It is expected that in December and the first quarter of 2025, various provinces will gradually implement the trade-in policy, relevant hospital tenders will be initiated, and equipment manufacturers are expected to see a large number of trade-in orders in the fourth quarter.
102884128 : getting disappointed with this counter. every day drop.